290 likes | 448 Views
The “LAW” and other Immunization Briefs. Lynn Bahta, RN, PHN Minnesota Department of Health May 2014. K-12 Requirements: Snapshot. Give Adolescents All Recommended Vaccines. Tdap HPV Meningococcal Influenza. Pertussis in Minnesota, 2013. Pertussis Prevention.
E N D
The “LAW” and other Immunization Briefs Lynn Bahta, RN, PHN Minnesota Department of Health May 2014
Give Adolescents All Recommended Vaccines • Tdap • HPV • Meningococcal • Influenza
Pertussis Prevention • Early diagnosis and treatment: think, test, treat • Reduce morbidity and mortality to most vulnerable – children under 1 year of age
Tdap Recommendations • Tdap at 11-12 y, then Td every 10 years (2006) • One Tdap for person 13 years or older not previously vaccinated, then Td every 10 years • Give Tdap regardless of interval since last Td • Tdap in incompletely or unvaccinated persons 7-9 y • ACIP off-label recommendation: use Tdap as one of the doses in the series • Update: Adacel now licensed to age 10 years, (Boostrix has been since first licensed)
Tdap Recommendations • Pregnant women • Tdap during every pregnancy regardless of the number of doses previously received, • Give between 27-36 weeks gestation
Key Tdap Law Implementation Issues • Tdap not necessary if dose given between ages 7-10 • Don’t need to consider waiting between last Td and Tdap • Can assume Td/Tdap documentation of older ages is likely Tdap
Serogroups C and Y account for the majority of meningococcal cases in adolescents
Recommendations for Routine Meningococcal Vaccination • Vaccines:Menactra (MCV4-D) or Menveo (MCV4-CRM) • Schedule:Routine adolescent • Give MCV4 at age 11-12 (2005) • MCV4 booster at age 16 (2011) • If first dose given at 13-15 years, give booster between 16-18 years • Minimum interval between doses is 8 weeks • If first dose given on of after age 16, a booster dose is not necessary • Catch-up through age 21 years if person is a first year college student living in residential housing UPDATE: Two vaccine candidates for serogroup B under FDA review
Key Meningococcal Law Implementation Issues • Phased AISR reporting • No booster dose reporting • Doses given before age 10 years not considered compliant (won’t protect through risk years) • Rates for upcoming 7th graders are sobering
Influenza • Return of H1N1 since 2009 pandemic • Incidence declining but still seeing B strains circulating • Less hospitalizations than last year but higher than recent years • Severe disease seen mostly in young and middle age adults
Influenza Laboratory Surveillance MN Lab System (MLS) Laboratory Influenza Surveillance Program Influenza week 17, 2014
New Influenza Vaccine Products • Flumist Quadrivalent (LAIV4), MedImmune • Fluarix Quadrivalent (IIV4), GSK • Fluzone Quadrivalent(IIV4), Sanofi Pasteur • Flulaval Quadrivalent (IIV4), ID Biomedical /GSK • Flulaval (IIV3) age expansion to 3 years, ID Biomedical/GSK • Flucelvax, a cell culture-based trivalent inactivated influenza vaccine (ccIIV3) ), Novartis • Flublok, a trivalent recombinant HA influenza vaccine (RIV3), Protein Sciences
Other Key Flu Messages • Efficacy • 50% give or take - mostly in healthy adults and children • Current flu vaccines are the most specific tool we have to reduce morbidity and mortality of influenza Timing of vaccination • Ideal: 2 weeks before onset of flu season • Real: impossible to predict the start of flu season! • Real: millions to vaccinate every season • Don’t miss the opportunity to vaccinate, there may not be another chance to do it
Pneumococcal Vaccination – Good to Know • Pneumococcal conjugate vaccine, 13 valent • Routinely recommended in infancy 2m, 4m, 6, 12-15m • Two vaccines, many older at-risk children need both • Pneumococcal conjugate vaccine (PCV13) • Conjugated technology allows for longer protection and more responsive boosting effect • Pneumococcal polysaccharide vaccine (PCV23) • Covers strains not included in 13-valent product • Preferable to give after conjugated product
Child Care & Early Childhood Program Requirements: a snapshot
Hepatitis A Included an outbreak that involved school-aged children
Hepatitis A Recommendations • Products: Havrix (GlaxoSmithKline) and Vaqta (Merck) • Age recommended: 12 Months • Schedule: 2 doses, at least 6 months apart • Immunization Rule: required for children in child care and early childhood education programs through Pre-kindergarten • Extended-day programs (K and up) are not included in this requirement
School-based Early Childhood Programs • Early childhood special education (ECSE) - has been included in the law for a couple decades • School-based early childhood programs • Children from birth through pre-kindergarten • Meet at least once a week for 6 or more weeks during the year • Vaccine requirements are the same as for child care
Early Childhood Law Implementation Q/A • Q: Do the new requirements only apply to newly enrolling kids? • A: No. Any child enrolled in child care or early childhood programs needs to meet the new requirements effective Sept 1, 2014. • Q: Are early childhood programs required to complete the Annual Immunization Status Report? • A: No, the Annual Immunization Status Report (AISR) is for K-12. • Q: How often should we check immunization records of children enrolled in Early Childhood programs? • A: Once during the school year is adequate.
Changes to Immunization Law • Implementation: September 1, 2014
Resources • Forms: www.health.state.mn.us/divs/idepc/immunize/tracking.html • Updates: Sign up for GovDelivery updates - click on the little red envelope on each of these pages: • School Health Personnel: www.health.state.mn.us/divs/idepc/immunize/school/ • Minnesota Immunization Rule Revisions: www.health.state.mn.us/divs/idepc/immunize/immrule/ Webex: https://health-state-mn-ustraining.webex.com/ • Select Recorded Sessions in the left navigation Questions? Call MDH: 651-201-5503 or 800-657-3970 or Email: health.immrule@state.mn.us